Trial Profile
A Phase II, Multicenter Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2017
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 09 Jun 2016 Status changed from active, no longer recruiting to completed.
- 22 Jan 2013 Planned end date changed from 1 Feb 2010 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.